| Serial Number | 97497975 |
| Word Mark | E-THERAPEUTICS |
| Filing Date | Monday, July 11, 2022 |
| Status | 686 - PUBLISHED FOR OPPOSITION |
| Status Date | Tuesday, October 15, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 20, 2024 |
| Goods and Services | Custom manufacture of pharmaceutical and medical preparations; custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid; none of the aforementioned services for, or related to, T-cells or T-cell receptors |
| Goods and Services | Downloadable and recorded computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; downloadable computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug discovery; downloadable databases in the field of pharmaceuticals, medicines and drug discovery; electronic databases recorded on computer media, for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded computer platform software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; downloadable and recorded computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the fields of pharmaceuticals, medicines and drug discovery; none of the aforementioned goods for, or related to, T-cells or T-cell receptors |
| Goods and Services | Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; none of the aforementioned goods for, or related to, T-cells or T-cell receptors |
| Goods and Services | Scientific research and development; pharmaceutical research and development services; scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; human genetic research; scientific and technical data analysis in the field of pharmaceuticals, medicines and drug discovery; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software; design, development, creation and maintenance of computational computer software platforms; design, development, creation and maintenance of computer software platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) featuring computer software platforms for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines, and drug discovery, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design and development of computer-simulated models; design of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations, for use in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS); Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and generating pharmaceutical and medical preparations; Software as a Service (SaaS) services featuring computer software platforms using artificial intelligence and machine learning for use in the field of pharmaceuticals, medicines and drug discovery, namely, for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid; none of the aforementioned services for, or related to, T-cells or T-cell receptors |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 29, 2022 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 29, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus. |
| US Class Codes | 021, 023, 026, 036, 038 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 29, 2022 |
| Primary Code | 009 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, July 29, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | E-THERAPEUTICS PLC |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | London W26BD GB |
| Party Name | E-THERAPEUTICS PLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | London W26BD GB |
| Event Date | Event Description |
| Thursday, July 14, 2022 | NEW APPLICATION ENTERED |
| Friday, July 29, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Wednesday, April 19, 2023 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Tuesday, April 25, 2023 | ASSIGNED TO EXAMINER |
| Thursday, April 27, 2023 | NON-FINAL ACTION WRITTEN |
| Thursday, April 27, 2023 | NON-FINAL ACTION E-MAILED |
| Thursday, April 27, 2023 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, June 26, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, November 30, 2023 | ASSIGNED TO LIE |
| Thursday, November 30, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, November 30, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, January 5, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Sunday, January 7, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, January 5, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Friday, January 5, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, January 5, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Friday, January 12, 2024 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Thursday, January 18, 2024 | ELECTRONIC RECORD REVIEW COMPLETE |
| Wednesday, January 31, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, January 31, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 20, 2024 | PUBLISHED FOR OPPOSITION |
| Monday, March 4, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 16, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Thursday, September 12, 2024 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
| Tuesday, October 15, 2024 | NOTICE OF ALLOWANCE CANCELLED |
| Tuesday, October 15, 2024 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Tuesday, October 15, 2024 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| Thursday, September 26, 2024 | TEAS DELETE 1(B) BASIS RECEIVED |